DNA vaccines for transplantation

Expert Opinion on Biological Therapy

Volumn 10, Issue 6, 2010, Pages 903-915

  Li, Alice F ^a   Escher, Alan ^a  

^a Transplantation Institute   (United States)

Author keywords

Alloimmunity; Apoptosis; Autoimmunity; DNA vaccine; Immune tolerance; Transplantation.

Indexed keywords

APOPTOTIC CELL VACCINE; CARDIAC MYOSIN; CD4 ANTIBODY; DENDRITIC CELL VACCINE; DNA VACCINE; GLUTAMATE DECARBOXYLASE 65; INTERLEUKIN 10; INTERLEUKIN 4; LYMPHOCYTE ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN BAX; RAPAMYCIN; UNCLASSIFIED DRUG; VACCINE;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ALLOTRANSPLANTATION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CHRONIC GRAFT REJECTION; DIABETES MELLITUS; DNA IMMUNIZATION; DRUG ADMINISTRATION ROUTE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INSULITIS; INTRATHYMIC DRUG ADMINISTRATION; LOW DRUG DOSE; NONHUMAN; PANCREAS TRANSPLANTATION; REVIEW; SKIN ALLOGRAFT; SURVIVAL TIME; TRANSPLANTATION; TREATMENT RESPONSE;

ANIMALS; AUTOIMMUNITY; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; TISSUE DONORS; TRANSPLANTATION IMMUNOLOGY; VACCINES, DNA;

ANIMALIA;

EID: 77952117132     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712591003796546     Document Type: Review

References (84)

1. Available from: www.unos.org
2. Makinodan T, Santos GW, Quinn RP. Immunosuppressive drugs. Pharmacol Rev 1970;22:189-247
3. Cecka JM, Terasaki PI, editors, Clinical transplants. UCLA Tissue Typing Laboratory, Los Angeles, California; 1997
4. Tantravahi J, Womer KL, Kaplan B. Why hasn't eliminating acute rejection improved graft survival? Annu Rev Med 2007;58:369-385
5. Billingham RE, Brent L, Medawar PB. 'Actively acquired tolerance' of foreign cells. Nature 1953;172:603-606 •• Seminal experiments on immune tolerance and its application to transplantation are described.
6. Monaco AP. Prospects and strategies for clinical tolerance. Transplant Proc 2004;36:227-231
7. Fehr T, Sykes M. Clinical experience with mixed chimerism to induce transplantation tolerance. Transpl Int 2008;21:1118-1135
8. LeGuern C. Tolerogenic property of MHC class I and class II molecules: lessons from a gene therapy approach. Front Biosci 2007;12:3133-3139
9. Luo B, Chan WF, Shapiro AM, Anderson CC. Non-myeloablative mixed chimerism approaches and tolerance, a split decision. Eur J Immunol 2007;37:1233-1242
10. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant 2008;8:1972-1981
11. Ponce R. Adverse consequences of immunostimulation. J Immunotoxicol 2008;5:33-41
12. Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev 2009;229:271-293
13. Alegre ML, Florquin S, Goldman M. Cellular mechanisms underlying acute graft rejection: time for reassessment. Curr Opin Immunol 2007;19:563-568
14. Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 2008;42:219-232
15. Garren H. DNA vaccines for autoimmune diseases. Expert Rev Vaccines 2009;8:1195-1203
16. Talmage DW, Dart G, Radovich J, Lafferty KJ. Activation of transplant immunity: effect of donor leukocytes on thyroid allograft rejection. Science 1976;191:385-388
17. Heeger PS. T-cell allorecognition and transplant rejection: a summary and update. Am J Transplant 2003;3:525-533
18. Lakkis FG, Sayegh MH. Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol 2003;14:2402-2410
19. G€okmen MR, Lombardi G, Lechler RI. The importance of the indirect pathway of allorecognition in clinical transplantation. Curr Opin Immunol 2008;20:568-574
20. Selander RK. Genetic variation in natural populations. In: Ayala FJ, editor, Molecular evolution. Sinauer Associates, Sunderland, MA; 1976. p. 21-45
21. Gnudi M, Webster JP. The life and times of Gaspare Tagliacozzi, surgeon of Bologna. Reichner, Bologna and New York; 1950. p. 1545-1599
22. Kuo E, Maruyama T, Fernandez F, Mohanakumar T. Molecular mechanisms of chronic rejection following transplantation. Immunol Res 2005;32:179-185
23. Delmas S, Picot MC, Vergnes C, et al. Risk factors of chronic rejection in kidney transplantation, results of a single center study. Nephrologie 1999;20:153-158
24. McDyer JF. Human and murine obliterative bronchiolitis in transplant. Proc Am Thorac Soc 2007;4:37-43
25. Fedoseyeva EV, Tam RC, Popov IA, et al. Induction of T cell responses to a self-antigen following allotransplantation. Transplantation 1996;61:679-683 •• Initial report on transplantation-induced autoimmunity showing that injection of allogeneic splenocytes results in breakdown of T cell tolerance to a self-peptide via an indirect alloresponse.
26. Sumpter TL, Wilkes DS. Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection. Am J Physiol Lung Cell Mol Physiol 2004;286:L1129-39
27. Benichou G, Alessandrini A, Charrad RS, et al. Induction of autoimmunity after allotransplantation. Front Biosci 2007;12:4362-4369
28. Boros P, Bromberg JS. De novo autoimmunity after organ transplantation: targets and possible pathways. Hum Immunol 2008;69:383-388
29. Mahesh B, Leong HS, McCormack A, et al. Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol 2007;170:1415-1427
30. Fukami N, Ramachandran S, Saini D, et al. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol 2009;182:309-318
31. Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007;117:3498-3506
32. Fedoseyeva EV, Kishimoto K, Rolls HK, et al. Modulation of tissue-specific immune response to cardiac myosin can prolong survival of allogeneic heart transplants. J Immunol 2002;169:1168-1174 • A study indicating that injection of antigen isolated from recipient heart before transplantation prolongs allograft survival of MHC class I-mismatched heart allograft in mice.
33. Yasufuku K, Heidler KM, O'Donnell PW, et al. Oral tolerance induction by type V collagen downregulates lung allograft rejection. Am J Respir Cell Mol Biol 2001;25:26-34
34. Yamada Y, Sekine Y, Yoshida S, et al. Type V collagen-induced oral tolerance plus low-dose cyclosporine prevents rejection of MHC class I and II incompatible lung allografts. J Immunol 2009;183:237-245 • A study showing that delivery of human collagen V before transplantation prolongs survival of fully mismatched lung allograft in immunosuppressed rats.
35. Lovegrove E, Pettigrew GJ, Bolton EM, Bradley JA. Epitope mapping of the indirect T cell response to allogeneic class I MHC: sequences shared by donor and recipient MHC may prime T cells that provide help for alloantibody production. J Immunol 2001;167:4338-4344 • Evidence that immunization with an epitope shared by recipient and donor can prolong donor cell survival in rodents is presented.
36. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-1468
37. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992;356:152-154
38. Cui Z. DNA vaccine. Adv Genet 2005;54:257-289
39. Jiang S, Herrera O, Lechler RI. New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance. Curr Opin Immunol 2004;16:550-557
40. Madsen JC, Superina RA, Wood KJ, Morris PJ. Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes. Nature 1988;332:161-164
41. Geissler EK, Wang J, Fechner JH Jr, et al. Immunity to MHC class I antigen after direct DNA transfer into skeletal muscle. J Immunol 1994;152:413-421
42. Knechtle SJ, Wang J, Graeb C, et al. Direct MHC class I complementary DNA transfer to thymus induces donor-specific unresponsiveness, which involves multiple immunologic mechanisms. J Immunol 1997;159:152-158 •• Among the first studies to show that direct injection of plasmid DNA coding for a donor antigen prolongs allograft survival.
43. Yamaguchi Y, Harland RC, Wyble C, Bollinger RR. The effect of pretreatment with class I major histocompatibility complex (MHC) antigens on hepatic or cardiac allograft survival in the rat. Transplant Proc 1989;21:3555 (Pubitemid 20145208)
44. Spriewald BM, Ensminger SM, Jenkins S, et al. Intrathymic delivery of plasmid-encoding endoplasmic reticulum signal-sequence-deleted MHC class I alloantigen can induce long-term allograft survival. Transpl Int 2004;17:458-462 • A study showing that DNA vaccine-encoded donor MHC I molecule presented via the indirect presentation pathway prolongs allograft survival.
45. Zhai Y, Hong X, Wang J, et al. Modulation of alloimmunity to major histocompatibility complex class I by cotransfer of cytokine genes in vivo. Transpl Immunol 1998;6:169-175
46. Pettigrew GJ, Lovegrove E, Bradley JA, et al. Indirect T cell allorecognition and alloantibody-mediated rejection of MHC class I-disparate heart grafts. J Immunol 1998;161:1292-1298
47. Pêche H, van Denderen B, Roussel JC, et al. Presentation of donor major histocompatibility complex class II antigens by DNA vaccination prolongs heart allograft survival. Transplantation 2004;77:733-740 • A study showing that peripheral delivery of plasmid DNA coding for donor MHC class II molecule, but not MHC class I molecule, prolongs allograft survival.
48. Doenecke A, Frank E, Scherer MN, et al. Prolongation of heart allograft survival after long-term expression of soluble MHC class I antigens and vIL-10 in the liver by AAV-plasmid-mediated gene transfer. Langenbecks Arch Surg 2008;393:343-348
49. Vignes C, Chiffoleau E, Brouard S, et al. Anti-TCR Vbeta-specific DNA vaccination prolongs heart allograft survival in adult rats. Eur J Immunol 2000;30:2460-2464 • A study using peripheral delivery of plasmid DNA coding for a recipient-specific antigen to prolong allograft survival.
50. Seifarth C, Pop S, Liu B, et al. More stringent conditions of plasmid DNA vaccination are required to protect grafted versus endogenous islets in nonobese diabetic mice. J Immunol 2003;171:469-476
51. Neu N, Rose NR, Beisel KW, et al. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol 1987;139:3630-3636
52. Fedoseyeva EV, Zhang F, Orr PL, et al. De novo autoimmunity to cardiac myosin after heart transplantation and its contribution to the rejection process. J Immunol 1999;162:6836-6842
53. Li A, Chen J, Hattori M, et al. A therapeutic DNA vaccination strategy for autoimmunity and transplantation. Vaccine 2010;28:1897-904 •• A study showing that injection of plasmid DNA coding for a shared antigen or a pro-apoptotic protein into recipient after transplantation prolongs fully mismatched skin allograft survival in immunosuppressed mice.
54. Valujskikh A, Fedoseyeva E, Benichou G, et al. Development of autoimmunity after skin graft rejection via an indirect alloresponse. Transplantation 2002;73:1130-1137
55. Williams MA, Trambley J, Ha J, et al. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts. J Immunol 2000;165:6849-6857
56. Kono T, Nishimura F, Sugimoto H, et al. Human fibroblasts ubiquitously express glutamic acid decarboxylase 65 (GAD 65): possible effects of connective tissue inflammation on GAD antibody titer. J Periodontol 2001;72:598-604
57. Ito K, Tanaka K, Nishibe Y, et al. GABA-synthesizing enzyme, GAD67, from dermal fibroblasts: evidence for a new skin function. Biochim Biophys Acta 2007;1770:291-296
58. Yu S, He X, Hu A, et al. Rapamycin combined with donor bone marrow-derived immature dendritic cells induces mouse skin allograft tolerance. Nan Fang Yi Ke Da Xue Xue Bao 2008;28:399-402
59. Rothstein DM, Livak MF, Kishimoto K, et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol 2001;166:322-329
60. Sho M, Kishimoto K, Harada H, et al. Requirements for induction and maintenance of peripheral tolerance in stringent allograft models. Proc Natl Acad Sci USA 2005;102:13230-13235
61. Chowdhury NC, Murphy B, Sayegh MH, et al. Acquired systemic tolerance to rat cardiac allografts induced by intrathymic inoculation of synthetic polymorphic MHC class I allopeptides. Transplantation 1996;62:1878-1882
62. Bittencourt MC, Perruche S, Contassot E, et al. Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers. Blood 2001;98:224-230 • A study showing that injection of recipient, donor, third party or xenogeneic apoptotic cells promotes donor bone marrow engraftment.
63. Kaneko K, Morelli AE, Wang Z, Thomson AW. Alloantigen presentation by ethylcarbodiimide-treated dendritic cells induces T cell hyporesponsiveness, and prolongs organ graft survival. Clin Immunol 2003;108:190-198
64. Wang Z, Shufesky WJ, Montecalvo A, et al. In situ-targeting of dendritic cells with donor-derived apoptotic cells restrains indirect allorecognition and ameliorates allograft vasculopathy. PLoS One 2009;4:e4940
65. Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998;339:1744-1751
66. Kirklin JK, Brown RN, Huang ST, et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung Transplant 2006;25:283-288
67. Lamioni A, Carsetti R, Legato A, et al. Induction of regulatory T cells after prophylactic treatment with photopheresis in renal transplant recipients. Transplantation 2007;83:1393-1396
68. Skoberne M, Beignon AS, Larsson M, Bhardwaj N. Apoptotic cells at the crossroads of tolerance and immunity. Curr Top Microbiol Immunol 2005;289:259-292
69. Giannoukakis N, Thomson A, Robbins P. Gene therapy in transplantation. Gene Ther 1999;6:1499-1511
70. Li XK, Okuyama T, Tamura A, et al. Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid. Transplantation 1998;66:1416-1423
71. Wang Y, Gao Y, Yuan X, et al. The liver mediates apoptotic cell-induced immune regulation. Scand J Immunol 2008;68:297-305
72. Isaacs JD. T cell immunomodulation -- the Holy Grail of therapeutic tolerance. Curr Opin Pharmacol 2007;7:418-425
73. Boros P, Bromberg JS. Human FOXP3+ regulatory T cells in transplantation. Am J Transplant 2009;9:1719-1724
74. Silk KM, Fairchild PJ. Harnessing dendritic cells for the induction of transplantation tolerance. Curr Opin Organ Transplant 2009;14:344-350
75. Scherer MN, Graeb C, Tange S, et al. Immunologic considerations for therapeutic strategies utilizing allogeneic hepatocytes: hepatocyte-expressed membrane-bound major histocompatibility complex class I antigen sensitizes while soluble antigen suppresses the immune response in rats. Hepatology 2000;32:999-1007
76. Graeb C, Justl M, Scherer MN, et al. Expression of high levels of soluble allogeneic major histocompatibility complex class I antigen by adenoviral gene transfer strongly inhibits allospecific cytotoxic T lymphocytes in vivo. Transplant Proc 2002;34:1398-1399
77. Gagne K, Brouard S, Guillet M, et al. TGF-beta1 and donor dendritic cells are common key components in donor-specific blood transfusion and anti-class II heart graft enhancement, whereas tolerance induction also required inflammatory cytokines down-regulation. Eur J Immunol 2001;31:3111-3120
78. Vignes C, Chiffoleau E, Douillard P, et al. Anti-TCR-specific DNA vaccination demonstrates a role for a CD8+ T cell clone in the induction of allograft tolerance by donor-specific blood transfusion. J Immunol 2000;165:96-101
79. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001;71:886-892
80. Iwata T, Philipovskiy A, Fisher AJ, et al. Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol 2008;181:5738-5747
81. Jiang H, Chess L. How the immune system achieves self-nonself discrimination during adaptive immunity. Adv Immunol 2009;102:95-133
82. Li AF, Hough J, Henderson D, Escher A. Co-delivery of pro-apoptotic BAX with a DNA vaccine recruits dendritic cells and promotes efficacy of autoimmune diabetes prevention in mice. Vaccine 2004;22:1751-1763
83. Li A, Ojogho O, Franco E, et al. Pro-apoptotic DNA vaccination ameliorates new onset of autoimmune diabetes in NOD mice and induces foxp3+ regulatory T cells in vitro. Vaccine 2006;24:5036-5046
84. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008;358:353-361